Mikogal (Cream, Suppositories) Instructions for Use
ATC Code
D01AC13 (Omoconazole)
Active Substance
Omoconazole (Rec.INN registered by WHO)
Clinical-Pharmacological Group
External antifungal drug
Pharmacotherapeutic Group
Antifungal agent
Pharmacological Action
The active substance, omoconazole nitrate, is an imidazole derivative and possesses antifungal and antibacterial properties.
The mechanism of action is based on blocking the biosynthesis of ergosterol and altering the lipid composition of fungi.
It acts fungistatically against yeasts ( Candida albicans, Candida glabrata and other Candida species), dermatophytes ( Trichophyton spp., Epidermophyton spp., Microsporum spp.), Pityrosporum orbiculare, Pityrosporum ovale, Aspergilus spp. According to in vitro studies, Omoconazole exerts a bactericidal effect against gram-positive bacteria.
Pharmacokinetics
When applied externally, it is not absorbed or is absorbed to a very small extent.
Indications
- Local treatment of fungal skin diseases;
- Candidiasis;
- Skin and hair diseases caused by dermatophytes: dermatophytosis of the hands and feet, smooth skin, tinea cruris, dermatophytosis of the scalp and beard area;
- Pityriasis versicolor;
- Seborrheic dermatitis caused by Pityrosporum ovale;
- Erythrasma.
ICD codes
| ICD-10 code | Indication |
| B35.0 | Mycosis of beard and head |
| B35.2 | Mycosis of hands |
| B35.3 | Tinea pedis |
| B35.4 | Tinea corporis |
| B35.6 | Tinea cruris |
| B36.0 | Pityriasis versicolor |
| B37.2 | Candidiasis of skin and nails |
| L08.1 | Erythrasma |
| L21 | Seborrheic dermatitis |
| ICD-11 code | Indication |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1F23.1Z | Candidiasis of skin or mucous membranes, unspecified |
| 1F28.2 | Dermatophytosis of foot |
| 1F28.3 | Genitofemoral dermatophytosis |
| 1F28.Y | Other specified dermatophytosis |
| 1F28.Z | Dermatophytosis, unspecified |
| 1F2D.0 | Pityriasis versicolor |
| EA81.Z | Seborrheic dermatitis, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Cream
For external use.
The cream is applied to the affected area of the skin 1-2 times/day in a thin layer and rubbed in gently.
Depending on the nature of the fungal disease, the average course of treatment is 2-6 weeks. Treatment should be continued for another week after complete recovery (disappearance of inflammation symptoms, subjective complaints) to prevent relapses of the disease.
Suppositories
Vaginal suppositories 150 mg: for 6 consecutive days in the evening, before going to bed, insert 1 suppository deep into the vagina.
Vaginal suppositories 300 mg: for 3 consecutive days in the evening, before going to bed, insert 1 suppository deep into the vagina.
Vaginal suppositories 900 mg: before going to bed, insert 1 suppository deep into the vagina.
Adverse Reactions
The drug is well tolerated. In some cases, local burning or mild skin irritation may be felt. In most cases, these symptoms are temporary and do not require discontinuation of treatment.
Contraindications
- Hypersensitivity to the components of the drug.
Use with caution during pregnancy and lactation.
Use in Pregnancy and Lactation
Animal studies have shown that in therapeutic doses, Omoconazole does not have an embryotoxic effect.
The use of Mikogal during pregnancy is possible only in cases where the potential benefit to the mother outweighs the possible risk to the fetus. If it is necessary to use the drug during lactation, the issue of discontinuing breastfeeding should be considered.
Special Precautions
Use with caution on large areas of damaged skin, when treating children under 5 years of age. Not recommended for use in patients sensitive to benzoic acid.
Do not apply to mucous membranes and the skin around the eyes.
Neutral or slightly alkaline soap should be used for washing the body. During treatment, underwear, towels, and washcloths should be disinfected and changed daily.
Drug Interactions
Not known.
Storage Conditions
Store in a place inaccessible to children at a temperature between 15°C (59°F) and 25°C (77°F).
Shelf Life
The shelf life is 3 years.
Dispensing Status
The drug is dispensed by prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Cream for external use 1%: tube 20 g
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Teva Pharmaceutical Works, Private Limited Company (Hungary)
Dosage Form
| Mikogal | Cream for external use 1%: tube 20 g |
Dosage Form, Packaging, and Composition
Cream for external use 1% white, homogeneous, odorless.
| 1 g | |
| Micronized omoconazole nitrate | 10 mg |
Excipients: light liquid paraffin, polysorbate 40, carbomer 934R, benzoic acid, sodium hydroxide (30% aqueous solution), Labrafil M-2130-CS (macrogol and palm oil glycerides esters), distilled water.
20 g – aluminum tubes (1) – cardboard packs.
Vaginal suppositories 150 mg: 6 pcs.
Vaginal suppositories 300 mg: 3 pcs.
Vaginal suppositories 900 mg: 1 pc.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Teva Pharmaceutical Works, Private Limited Company (Hungary)
Dosage Forms
| Mikogal | Vaginal suppositories 150 mg: 6 pcs. | |
| Vaginal suppositories 300 mg: 3 pcs. | ||
| Vaginal suppositories 900 mg: 1 pc. |
Dosage Form, Packaging, and Composition
Vaginal suppositories white or almost white, homogeneous, cylindrical.
| 1 supp. | |
| Micronized omoconazole nitrate | 150 mg |
Excipients: hard fat (Witepsol W25).
6 pcs. – non-cell contour packages made of aluminum foil coated with polyethylene (1) – cardboard packs.
Vaginal suppositories white or almost white, homogeneous, cylindrical.
| 1 supp. | |
| Micronized omoconazole nitrate | 300 mg |
Excipients: hard fat (Witepsol W25).
3 pcs. – non-cell contour packages made of aluminum foil coated with polyethylene (1) – cardboard packs.
Vaginal suppositories white or almost white, homogeneous, cylindrical.
| 1 supp. | |
| Micronized omoconazole nitrate | 900 mg |
Excipients: hard fat (Witepsol W25).
1 pc. – non-cell contour packages made of aluminum foil coated with polyethylene (1) – cardboard packs.
